Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12345678910111213...136137»
  • ||||||||||  Journal:  Thymoma With Myasthenia Gravis: A Study of Two Cases. (Pubmed Central) -  Sep 25, 2024   
    Complete surgical resection remains the cornerstone of treatment, with adjuvant therapy tailored based on individual risk factors. Ongoing surveillance is crucial for identifying potential recurrences and associated conditions.
  • ||||||||||  Review, Journal:  Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis. (Pubmed Central) -  Sep 25, 2024   
    Additionally, the network between these noncoding RNAs, such as the competing endogenous RNA regulatory network, has been found to be involved in MG progression. In this review, we summarized the roles of miRNA, lncRNA, and circRNA, highlighted their potential application as biomarkers in diagnosing MG, and discussed their potential regulatory networks in the abnormal thymus and PBMCs during MG development.
  • ||||||||||  A Patient-Focused Program for Using Steroids Wisely (In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2665;    
    Mimetic cells are evolutionarily ancient, having been conserved from zebrafish to mouse to man. Steroids and Me (SAM) is a unique patient-focused resource that engages, educates, and equips users to understand and reduce steroid-toxicity, facilitating conversations that foster shared decision making around steroid use.
  • ||||||||||  Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease (Room 144ABC; In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_912;    
    This study demonstrates the feasibility of conducting comprehensive multi-omics analyses on PBMCs from patients with autoimmune disease pre- and post-CAR T-cell therapy. The observed molecular signatures in immune cell subsets represent promising avenues for future investigations into the mechanisms underlying the clinical effects of CAR T-cell therapy in autoimmune disease.
  • ||||||||||  Journal, IO biomarker:  Diagnostic value of antibody concentration ratio for treatment-refractory myasthenia gravis. (Pubmed Central) -  Sep 24, 2024   
    The observed molecular signatures in immune cell subsets represent promising avenues for future investigations into the mechanisms underlying the clinical effects of CAR T-cell therapy in autoimmune disease. Elevated Antibody Concentration Ratio is intrinsically linked with refractory MG and exhibits potential as an diagnostic biomarker for the condition.
  • ||||||||||  Journal:  Seronegative Myasthenia Gravis: A Rare Disease Triggered by SARS-CoV-2 or a Coincidence? (Pubmed Central) -  Sep 24, 2024   
    Although the exact cause is not fully understood, it is known that the onset and exacerbations of MG can occur after viral infections. We present the case of a patient with no prior history of MG with new-onset proximal muscle weakness and ptosis, following SARS-CoV-2 infection, This case underscores the potential for autoimmune diseases to be triggered by SARS-CoV-2.
  • ||||||||||  Journal:  Atypical Presentations of Myasthenia Gravis as Acute Respiratory Failure: A Rare Case. (Pubmed Central) -  Sep 24, 2024   
    This makes the management of respiratory comorbidities essential, as respiratory tract infections can lead to exacerbations of MG and trigger a myasthenic crisis, necessitating immediate medical intervention. This report highlights a patient who initially presented with acute respiratory distress and was subsequently diagnosed with MG, underscoring the importance of recognizing respiratory symptoms in the context of this condition.
  • ||||||||||  Journal:  CGG/CCG Repeat Expansions in LOC642361/NUTM2B-AS1 in Thai Patients With Oculopharyngodistal Myopathy. (Pubmed Central) -  Sep 23, 2024   
    While initially characterized as oculopharyngeal myopathy with leukoencephalopathy (OPML) in a Japanese family, our study suggests a stronger association between CGG/CCG expansion in LOC642361/NUTM2B-AS1 and oculopharyngodistal myopathy (OPDM) rather than OPML. The variable presence or absence of leukoencephalopathy further supports OPDM as the predominant clinical manifestation linked to CGG/CCG expansion in LOC642361/NUTM2B-AS1.
  • ||||||||||  Bridion (sugammadex) / Merck (MSD)
    Review, Journal:  Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity. (Pubmed Central) -  Sep 21, 2024   
    These uncontrolled observations (of mainly low to moderate quality and validity) do not allow confident assessment of the efficacy and safety of sugammadex for the reversal of NMBAs in patients with neuromuscular diseases. Reporting of observational data should follow established guidelines, include specific information to ensure validity, and emphasise what the new data add to current knowledge.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  The Risk of Falls Index for Patients With Neuromuscular Disorders (clinicaltrials.gov) -  Sep 20, 2024   
    P=N/A,  N=30, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Sep 2025 --> Sep 2024 | Trial primary completion date: Sep 2025 --> Sep 2024
  • ||||||||||  Enrollment change, Trial completion date, Trial primary completion date:  Oxaloacetate in Myasthenia Gravis (clinicaltrials.gov) -  Sep 20, 2024   
    P1,  N=24, Not yet recruiting, 
    Recruiting --> Completed | Trial completion date: Sep 2025 --> Sep 2024 | Trial primary completion date: Sep 2025 --> Sep 2024 N=12 --> 24 | Trial completion date: Apr 2023 --> Dec 2026 | Trial primary completion date: Apr 2023 --> Aug 2026
  • ||||||||||  Preclinical, Journal:  Agonist antibody to MuSK protects mice from MuSK myasthenia gravis. (Pubmed Central) -  Sep 20, 2024   
    The disease can be prevented by a MuSK agonist antibody, presented either prophylactically or after disease onset. These findings suggest a therapeutic alternative to generalized immunosuppression for treating MuSK MG by selectively and directly targeting the disease mechanism.
  • ||||||||||  Journal:  Cardiac implications in myasthenia gravis. (Pubmed Central) -  Sep 20, 2024   
    The study supports the significance of thymoma, antistriational antibodies, and late-onset MG as key factors associated with cardiac involvement in MG patients. It emphasizes the importance of ECG as the initial test in managing MG patients, particularly in the perioperative period, to identify and genetic testing if needed to address their cardiac risk effectively.
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis
    Journal:  Omalizumab-induced ocular myasthenia gravis? (Pubmed Central) -  Sep 19, 2024   
    It emphasizes the importance of ECG as the initial test in managing MG patients, particularly in the perioperative period, to identify and genetic testing if needed to address their cardiac risk effectively. No abstract available
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    New P3 trial:  Seronegative Myasthenia Gravis - Efgartigimod IV (clinicaltrials.gov) -  Sep 19, 2024   
    P3,  N=30, Recruiting, 
  • ||||||||||  Journal:  Sero-Positive Isolated Ocular Myasthenia Gravis. (Pubmed Central) -  Sep 17, 2024   
    The patient demonstrated significant improvement in ptosis and diplopia. There are still a considerable number of challenges in the diagnosis and treatment of ocular myasthenia gravis, with the typical treatment involving acetylcholinesterase inhibitors and immunosuppressants.
  • ||||||||||  Review, Journal:  Type 2 hypersensitivity disorders, including systemic lupus erythematosus, Sj (Pubmed Central) -  Sep 15, 2024   
    There are still a considerable number of challenges in the diagnosis and treatment of ocular myasthenia gravis, with the typical treatment involving acetylcholinesterase inhibitors and immunosuppressants. Similarly, the type 2 hypersensitivity disorders myasthenia gravis, Graves' disease, graft-versus-host disease, autoimmune haemolytic anaemia, immune thrombocytopenia, dermatomyositis, and Sj